Skip to main content
NewslettersWatchlist

Cybin Inc(CYBN-NE)
Cboe CA

Today's Change
Real-Time Last Update
Day Low14.7000
Day High16.0000
Open:16.0000
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
the globe and mail
the globe and mail

Can Canada’s psychedelic drug developers shake off the sector’s bad trip?

Cybin, MindMed are set to launch expanded human studies after recent trial setbacks for Lykos, Compass
Business Wire
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Business Wire
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
Business Wire
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
Business Wire
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
Business Wire
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
Business Wire
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
Business Wire
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
Newsfile
A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update
Newsfile
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023
Newsfile
Cybin to Acquire Small Pharma Inc.
Business Wire
Cybin to Participate at the 26th Annual Milken Institute Global Conference
Business Wire
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy
Business Wire
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference
Investor Brand Network
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder in Psychedelics Discussions
Business Wire
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference
Business Wire
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
Business Wire
Cybin Announces Streamlined Clinical Alignment
Investor Brand Network
Cybin (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report
Business Wire
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
Business Wire
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
Investor Brand Network
Cybin (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day
Business Wire
Cybin to Host Virtual R&D Day on February 28, 2023

Profile

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.